Related Experiment Videos
Kill 'Em All: Efgartigimod Immunotherapy for Autoimmune Diseases
Jagadeesh Bayry1, Srini V Kaveri1
1Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Université Paris Descartes, Sorbonne Paris Cité, Paris, F-75006, France.
Trends in Pharmacological Sciences
|September 12, 2018
Summary
Neonatal Fc receptors (FcRn) recycle immunoglobulins G (IgGs), prolonging the half-life of pathogenic auto-IgGs. Inhibitors targeting this IgG-FcRn interaction, like efgartigimod, are being developed for autoimmune disease treatment.
Area of Science:
- Immunology
- Pharmacology
- Biochemistry
Background:
- Neonatal Fc receptors (FcRn) play a crucial role in recycling immunoglobulin G (IgG) by preventing its degradation.
- This recycling mechanism extends the half-life of IgG, including pathogenic auto-IgGs implicated in autoimmune diseases.
Purpose of the Study:
- To explore inhibitors of the IgG-FcRn interface as a therapeutic strategy for autoimmune diseases.
- To investigate the potential of engineered Fc molecules, inspired by intravenous immunoglobulin mechanisms, for autoimmune disease treatment.
Main Methods:
- Development of high-affinity FcRn-binding engineered Fc molecules.
- Preclinical and clinical evaluation of FcRn inhibitors, including efgartigimod.
Main Results:
- Engineered Fc molecules with high affinity for FcRn have been designed.
- Efgartigimod, an engineered Fc molecule, has successfully completed Phase I clinical trials.
Conclusions:
- Inhibiting the IgG-FcRn interaction is a promising therapeutic approach for autoimmune diseases.
- Efgartigimod represents a potential new treatment modality for autoimmune conditions.